Posted by Michael Wonder on 29 Jun 2024
Mirum submits new drug application to FDA for chenodiol for the treatment of CTX
28 June 2024 - Mirum Pharmaceuticals today announced the submission of a new drug application for chenodiol for the treatment of patients in the US with cerebrotendinous xanthomatosis.
The submission of the new drug application is based on the positive results of the Phase 3 RESTORE study which evaluated chenodiol in adult patients with cerebrotendinous xanthomatosis.
